nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
The general name metallocene is derived from ferrocene, (C5H5)2Fe or Cp2Fe, systematically named bis(η5-cyclopentadienyl)iron(II). According to the International Union of Pure and Applied Chemistry (IUPAC) definition, a metallocene contains a transition metal and two cyclopentadienyl ligands coordinated in a sandwich structure, i.e., the two cyclopentadienyl anions are on parallel planes with equal bond lengths and strengths. Using the nomenclature of "hapticity", the equivalent bonding of all 5 carbon atoms of a cyclopentadienyl ring is denoted as η5, pronounced "pentahapto". In metallocene names, the prefix before the -ocene ending indicates what metallic element is between the Cp groups. For example, in ferrocene, iron(II), ferrous iron is present.
At first, common carrier was only limited to a small area around Los Angeles but by 1927 expanded to areas up to 125 miles outside the city. In 1924, a conveyor belt system was debuted for the handling of packages for UPS operations. In 1930, a consolidated carrier service began in New York City; soon after, the company expanded its services to include other major cities in the East and the Midwest. The use of a common carrier for delivery between all customers placed UPS in direct competition with USPS, and delivering parcels beyond the California border brought it under the jurisdiction of the Interstate Commerce Commission. The first city for UPS to use common carrier status outside California was Chicago, Illinois, in 1953.
The Israel Defense Forces "battle ration" (Manat Krav) is designed to be shared by four soldiers. It contains 1 can of rice filled vine leaves, 8 small cans of tuna, canned olives, a can of sweet corn, a can of pickled cucumbers, 1 can of halva spread and 1 chocolate spread, a can of peanuts, fruit flavored drink powder, and bread or matzoh crackers. There is also an "ambush pack" of candy and high-energy protein bars. In 2008, Israel introduced a new field ration to supplement the traditional Manat Krav. Unlike previous rations, the new Battle Ration consists of individual, self-heating, ready-to-eat meals packed inside plastic-aluminum trays. They are designed to be carried and used by infantry troops for up to 24 hours, until regular supply lines can be established. Ten menus are available, including chicken, turkey and kebab; each meal pack is supplemented with dry salami, dried fruit, tuna, halva, sweet roll, and preserved dinner rolls. However, as of 2012, the older rations were still in use. In 2011, as a result of the manufacturer going bankrupt, the IDF phased out the can of corned beef (known as 'Loof'), which had been part of the battle ration since the nation's founding. It would be replaced by "ground meat with tomato sauce". Many different recipes and different ways of serving the rations have developed in Israel. With the can of tuna, for example, traditionally cooked using toilet paper soaked in oil.
reduced riboflavin + NADP+ Thus, the two products of this enzyme are reduced riboflavin and NADP+, whereas its 3 substrates are riboflavin, NADPH, and H+. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is reduced-riboflavin:NADP+ oxidoreductase. Other names in common use include flavine mononucleotide (FMN) reductase, FMN reductase (NADPH), NADPH-dependent FMN reductase, NADPH-flavin reductase, NADPH-FMN reductase, NADPH-specific FMN reductase, NADPH2 dehydrogenase (flavin), NADPH2:riboflavin oxidoreductase, NADPH:flavin oxidoreductase, riboflavin mononucleotide reductase, riboflavine mononucleotide reductase and riboflavin mononucleotide (reduced nicotinamide adenine dinucleotide, phosphate) reductase.
Hong Kong is home to a wide range of museums, galleries, and cultural institutions, and is regarded as one of Asia's leading centres for art, heritage, and visual culture. Major cultural development in the city has taken place in the West Kowloon Cultural District, a large arts and museum quarter on reclaimed land in Kowloon. Its best-known institutions include M+, a museum of visual culture focused on 20th and 21st century art, design, architecture, and moving image, and the Hong Kong Palace Museum, which displays Chinese artworks and artifacts. Apart from West Kowloon, Hong Kong has many additional museums across the territory. The Hong Kong Museum of Art in Tsim Sha Tsui houses collections of Chinese antiquities, calligraphy, painting, and Hong Kong art. The Hong Kong Heritage Museum in Sha Tin focuses on history, art, and local popular culture, with exhibitions on Cantonese opera, film, and design. The Hong Kong Museum of History presents the development of Hong Kong from prehistoric times to the present, while the Hong Kong Science Museum and Hong Kong Space Museum are among the city's main public institutions devoted to science and education. Tai Kwun, a former police station and prison compound in Central, has been revitalised as a centre for heritage and contemporary art, and hosts exhibitions, performances, and public programmes.
Sources: en.wikipedia.org
=== Agriculture === Ectomycorrhizal fungi are not prominent in agricultural and horticultural systems. Most of the economically relevant crop plants that form mycorrhizas tend to form them with arbuscular mycorrhizal fungi. Many modern agricultural practices such as tillage, heavy fertilizers and fungicides are extremely detrimental to mycorrhizas and the surrounding ecosystem. It is possible that agriculture indirectly affects nearby ectomycorrhizal species and habitats; for example, increased fertilization decreases sporocarp production.
== Evolution == Many scientific studies throughout the past half century have used porcine aminoacylase as their model aminoacylase enzyme. The amino acid sequence and primary structure of porcine aminoacylase have been determined. Porcine aminoacylase 1 is composed of two identical heterodimeric subunits each consisting of 406 amino acids, with acetylalanine at the N-terminus of each. Porcine aminoacylase differs from human aminoacylase in structure but replicates its function. It can be inferred from this data that these two enzymes evolved from a common ancestral protein, retaining function but diverging in structure over time.
Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
=== Official discovery and later history === The discovery of element 43 was finally confirmed in a 1937 experiment at the University of Palermo in Sicily by Carlo Perrier and Emilio Segrè. In mid-1936, Segrè visited the United States, first Columbia University in New York and then the Lawrence Berkeley National Laboratory in California. He persuaded cyclotron inventor Ernest Lawrence to let him take back some discarded cyclotron parts that had become radioactive. Lawrence mailed him a molybdenum foil that had been part of the deflector in the cyclotron. Segrè enlisted his colleague Perrier to attempt to prove, through comparative chemistry, that the molybdenum activity was indeed from an element with the atomic number 43, which they did. University of Palermo officials wanted them to name their discovery panormium, after the Latin name for Palermo, Panormus. In 1947, element 43 was named after the Greek word technetos (τεχνητός), meaning 'artificial', since it was the first element to be artificially produced. Segrè returned to Berkeley and met Glenn T. Seaborg. They isolated the metastable isotope technetium-99m, which is now used in some ten million medical diagnostic procedures annually. In 1952, the astronomer Paul W. Merrill detected the spectral signature of technetium (specifically wavelengths of 403.1 nm, 423.8 nm, 426.2 nm, and 429.7 nm) in light from S-type red giants. The stars were near the end of their lives but were rich in the short-lived element, which indicated that it was being produced in the stars by nuclear reactions.
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. It was approved for use in Japan in 2014. In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 IU/L) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome.
Sources: en.wikipedia.org
=== 2009 === In February 2009, the International Institute for Strategic Studies published an annual report, Military Balance 2009. The report said that Russian forces were well-prepared for the August war and the Russian military operation was strategically well-planned. In 2009, Martin Malek, a researcher at the Institute for Peace Support and Conflict Management of the National Defense Academy in Vienna, noted that in September 2008, the Valdai Discussion Club was told by Vladimir Putin about his August 8 meeting with Chinese officials in Beijing and discussion of the recognition of Abkhazia and South Ossetia; Malek concluded that 8 August 2008 was the latest date when the recognition of Abkhazia and South Ossetia was considered or "possibly already decided". Malek concluded that due to the anti-American bias of the western Europeans and mass dislike of George W. Bush, the western media was keen to put the blame for the war on the pro-American Georgian government. In May 2009, Kaarel Kaas wrote an article for International Centre for Defense Studies, where he noted that this war was the first time since the fall of the Soviet Union that the Russian military had been used against an independent state, demonstrating Russia's willingness to use military force to attain its political objectives. Kaas wrote, "The military operation was only one phase in a longer-term anti-Georgian campaign.
=== Treatment and prevention === Treatment and prevention of periwound issues are becoming increasingly important as research continues to confirm the role of periwound in wound healing. The shared objective of treatment and prevention is maintenance and/or restoration of the integrity and healthy functionality of skin surrounding the wound. Main treatment and prevention strategies include the following:
For this reason, people who consume corn as tortillas or hominy are at less risk of niacin deficiency. For treating deficiency, the World Health Organization (WHO) recommends administering nicotinamide instead of nicotinic acid, to avoid the flushing side effect commonly caused by the latter. Guidelines suggest using 300 mg/day for three to four weeks. Dementia and dermatitis show improvement within a week. Because deficiencies of other B-vitamins may be present, the WHO recommends a multi-vitamin in addition to the nicotinamide. Hartnup disease is a hereditary nutritional disorder resulting in niacin deficiency. It is named after an English family with a genetic disorder that resulted in a failure to absorb the essential amino acid tryptophan, tryptophan being a precursor for niacin synthesis. The symptoms are similar to pellagra, including red, scaly rash and sensitivity to sunlight. Oral nicotinic acid or nicotinamide is given as a treatment for this condition in doses ranging from 50 to 100 mg twice a day, with a good prognosis if identified and treated early. Niacin synthesis is also deficient in carcinoid syndrome, because of metabolic diversion of its precursor tryptophan to form serotonin.
The mortality rate from variola minor is approximately 1%, while the mortality rate from variola major is approximately 30%. Ordinary type-confluent is fatal about 50–75% of the time, ordinary-type semi-confluent about 25–50% of the time, in cases where the rash is discrete the case-fatality rate is less than 10%. The overall fatality rate for children younger than 1 year of age is 40–50%. Hemorrhagic and flat types have the highest fatality rates. The fatality rate for flat or late hemorrhagic type smallpox is 90% or greater and nearly 100% is observed in cases of early hemorrhagic smallpox. The case-fatality rate for variola minor is 1% or less. There is no evidence of chronic or recurrent infection with variola virus. In cases of flat smallpox in vaccinated people, the condition was extremely rare but less lethal, with one case series showing a 67% death rate. In fatal cases of ordinary smallpox, death usually occurs between days 10–16 of the illness. The cause of death from smallpox is not clear, but the infection is now known to involve multiple organs. Circulating immune complexes, overwhelming viremia, or an uncontrolled immune response may be contributing factors. In early hemorrhagic smallpox, death occurs suddenly about six days after the fever develops. The cause of death in early hemorrhagic cases is commonly due to heart failure and pulmonary edema. In late hemorrhagic cases, high and sustained viremia, severe platelet loss and poor immune response were often cited as causes of death.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.